6/24/2020

IBRI RESEARCH PUBLISHED: Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes

Abstract The protein hormone adiponectin regulates glucose and fatty acid metabolism by bindin...

6/15/2020

IBRI IN THE NEWS: Biosciences Institute Develops Diagnosis Technologies

INDIANAPOLIS - The Indiana Biosciences Research Institute in Indianapolis has completed develop...

6/11/2020

IBRI Develops Technologies that Help to Diagnose Diseases Faster, More Accurately

INDIANAPOLIS, IND. - The Indiana Biosciences Research Institute (IBRI), a leading independent, indus...

6/9/2020

IBRI and TBH Creative Win Gold Aster Award

We were pleased to partner with TBH Creative to move our 2018 Annual Report from print to online. TB...

6/3/2020

IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes

Abstract: Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss o...

5/29/2020

IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine

The race is on. Around the world, more than 80 vaccine projects are under development by pharmaceut...

5/26/2020

New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D

INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leadi...

5/13/2020

IBRI RESEARCH PUBLISHED: Pancreatic ß-cells in Type 1 and Type 2 Diabetes Mellitus: Different Pathways to Failure

Abstract: Loss of functional β-cell mass is the key mechanism leading to the two main for...

4/16/2020

IBRI IN THE NEWS: IBRI Names Scientific Director

INDIANAPOLIS - The Indiana Biosciences Research Institute has named Investigator Decio Eizirik ...

4/15/2020

IBRI Names Decio Eizirik Scientific Director of its IBRI Diabetes Center

INDIANAPOLIS, IND. – The Indiana Biosciences Research Institute (IBRI) is pleased to announce ...

 1 2 3 4 5  ... Last 

2019 Annual Report cover

The IBRI 2019 Annual Report is now available. The report theme is “Catalyze, Complement, Connect,” which correlates with the IBRI's goals to seek solutions for health problems, enhance the Indiana life sciences ecosystem, and expedite solutions for the most pressing health issues.